Celldex Therapeutics (CLDX) Earnings Call Presentation

Barzolvolimab Phase 2 CSU 76 Week Data 7 MONTHS POST ACTIVE THERAPY 2 01 Introduction Anthony Marucci, President & CEO 3 Barzolvolimab Best in Disease for All Patients1 EAACI 2025 Safe Harbor Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our us ...